MoonLake Immunotherapeutics Statistics
Share Statistics
MoonLake Immunotherapeutics has 63.06M shares outstanding. The number of shares has increased by 0.99% in one year.
| Shares Outstanding | 63.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.84M |
| Failed to Deliver (FTD) Shares | 129 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 8.04M, so 12.75% of the outstanding shares have been sold short.
| Short Interest | 8.04M |
| Short % of Shares Out | 12.75% |
| Short % of Float | 15.21% |
| Short Ratio (days to cover) | 44.41 |
Valuation Ratios
The PE ratio is -82.39 and the forward PE ratio is -20.67.
| PE Ratio | -82.39 |
| Forward PE | -20.67 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 5.98 |
| P/FCF Ratio | -68.89 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for MoonLake Immunotherapeutics.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 51.59, with a Debt / Equity ratio of 0.
| Current Ratio | 51.59 |
| Quick Ratio | 51.59 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.07% and return on capital (ROIC) is -10.49%.
| Return on Equity (ROE) | -0.07% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -10.49% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -720.15K |
| Employee Count | 50 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 94.39K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -19.32% in the last 52 weeks. The beta is 1.28, so MoonLake Immunotherapeutics's price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | -19.32% |
| 50-Day Moving Average | 51.69 |
| 200-Day Moving Average | 46.9 |
| Relative Strength Index (RSI) | 36.7 |
| Average Volume (20 Days) | 233.80K |
Income Statement
| Revenue | n/a |
| Gross Profit | -13.16K |
| Operating Income | -54.12M |
| Net Income | -36.01M |
| EBITDA | -54.11M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.73 |
Balance Sheet
The company has 451.17M in cash and 3.81M in debt, giving a net cash position of 447.36M.
| Cash & Cash Equivalents | 451.17M |
| Total Debt | 3.81M |
| Net Cash | 447.36M |
| Retained Earnings | -116.66M |
| Total Assets | 518.21M |
| Working Capital | 492.24M |
Cash Flow
In the last 12 months, operating cash flow was -42.78M and capital expenditures -284.63K, giving a free cash flow of -43.06M.
| Operating Cash Flow | -42.78M |
| Capital Expenditures | -284.63K |
| Free Cash Flow | -43.06M |
| FCF Per Share | -0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.57% |
| FCF Yield | -1.47% |
Analyst Forecast
The average price target for MLTX is $73, which is 56.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $73 |
| Price Target Difference | 56.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 88.98 |
| Piotroski F-Score | 2 |